FIELD: biotechnology.
SUBSTANCE: antibody is proposed, which specifically binds to CD47. In addition, nucleic acid encoding the specified antibody, a vector containing the specified nucleic acid, a host cell for the production of the antibody, containing the specified vector, are proposed. In addition, the invention relates to methods for induction of phagocytosis of cells expressing CD47, and to methods for the treatment of malignant neoplasm.
EFFECT: invention allows for induction of phagocytosis of cells expressing CD47, without causing sufficient hemagglutination.
36 cl, 44 dwg, 18 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ANTIBODY COMPOSITIONS FOR CANCER IMMUNOTHERAPY | 2019 |
|
RU2804490C2 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| EMBODIMENTS OF IGG-Fc FOR USE IN VETERINARY SCIENCE | 2018 |
|
RU2814952C2 |
| IMPROVED SYNTHETIC T-CELL RECEPTOR AND ANTIGEN RECEPTOR | 2021 |
|
RU2820497C1 |
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODIES TO PCSK-9, AND ITS USE | 2018 |
|
RU2782792C2 |
| NOVEL PROTEIN COMPOSITIONS OBTAINED BY RATIONAL DESIGN | 2019 |
|
RU2816719C2 |
| ANTIBODY AGAINST CLAUDIN 18A2 AND ITS USE | 2020 |
|
RU2811431C2 |
| NEW ANTI-C-MET-ANTIBODY AND APPLICATION THEREOF | 2018 |
|
RU2751720C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| ANTI-LILRB1 ANTIBODY AND ITS USE | 2020 |
|
RU2801535C1 |
